P2X purinoceptor 7 (P2RX7) (P2RX7)

The P2X purinoceptor 7 (P2RX7) is a trimeric ligand-gated ion channel that serves as a key sensor for extracellular adenosine triphosphate (ATP), a damage-associated molecular pattern (DAMP) released during cell injury (UniProt P51575). Upon binding high concentrations of ATP, P2RX7 facilitates the rapid efflux of potassium ions (K+) from the cytosol, which is recognized as a primary stimulus for the activation of the NLRP3 inflammasome (He et al., 2016, Nature Communications). This activation leads to the proteolytic cleavage of pro-caspase-1 and the subsequent maturation and secretion of potent pro-inflammatory cytokines, specifically interleukin-1 beta (IL-1β) and interleukin-18 (IL-18) (PubMed: 26479925). Due to its central role in mediating chronic inflammation and neuroinflammation, P2RX7 is a significant therapeutic target for conditions such as rheumatoid arthritis, Crohn's disease, and Alzheimer's disease (StatPearls: Purinergic Receptors). Pharmacological inhibition of P2RX7, using antagonists like AZD9056 or JNJ-54175446, aims to suppress the overactive inflammatory response by blocking the ionic flux necessary for inflammasome assembly (ClinicalTrials.gov). Beyond its role in cytokine release, P2RX7 also influences cell death pathways and the release of other inflammatory mediators, making it a versatile target in immunology and neurology (PubMed: 24492097).

Other names

P2X7 receptorPurinergic receptor P2X7P2Z receptorATP-gated ion channel P2X7P2RX7

Antagonism of the P2X7 receptor to inhibit ATP-dependent potassium (K+) efflux, thereby preventing the conformational change and assembly of the NLRP3 inflammasome complex (Munoz-Planillo et al., 2013, Immunity).